6 research outputs found
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Background Liraglutide 3\ub70 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3\ub70 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2\ub77 times longer with liraglutide than with placebo (95% CI 1\ub79 to 3\ub79, p<0\ub70001), corresponding with a hazard ratio of 0\ub721 (95% CI 0\ub713\u20130\ub734). Liraglutide induced greater weight loss than placebo at week 160 (\u20136\ub71 [SD 7\ub73] vs 121\ub79% [6\ub73]; estimated treatment difference 124\ub73%, 95% CI 124\ub79 to 123\ub77, p<0\ub70001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3\ub70 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding Novo Nordisk, Denmark
Π€ΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Ρ ΡΠ°Π½ΠΈΠ»ΠΈΡΠ° ΠΈ Π°Π½Π°Π»ΠΈΠ· Π±ΠΎΠ»ΡΡΠΈΡ Π΄Π°Π½Π½ΡΡ ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΠΉ Π² Π³ΠΎΡΠΎΠ΄Π΅
Π ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Π° ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΡ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ Ρ
ΡΠ°Π½ΠΈΠ»ΠΈΡΠ° Π΄Π°Π½Π½ΡΡ
ΠΏΡΡΠ΅ΠΉ ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ Π΄Π»Ρ ΠΈΠ½ΡΠ΅Π»Π»Π΅ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π³ΠΎΡΠΎΠ΄Π°. ΠΡΠΈΠ²Π΅Π΄Π΅Π½ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΠΏΠΏΠ°ΡΠ°Ρ ΡΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΠΈΡΠ°Π½ΠΈΡ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π³ΠΈΠΏΠ΅ΡΡΠ΅ΡΠΈ, Π΄ΡΠ³ΠΈ ΠΊΠΎΡΠΎΡΠΎΠΉ ΡΠ²Π»ΡΡΡΡΡ ΠΏΡΡΡΠΌΠΈ ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ. Π Π°ΡΡΠΌΠΎΡΡΠ΅Π½ ΡΠ΅ΠΊΡΡΡΠΈΠ²Π½ΡΠΉ Π°Π»Π³ΠΎΡΠΈΡΠΌ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ Π΄Π°Π½Π½ΡΡ
ΠΎ ΠΏΡΡΡΡ
ΠΏΠ΅ΡΠ΅Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ°ΡΡΠΈΡ ΡΠΌΠ΅ΠΆΠ½ΠΎΡΡΠΈ ΠΏΠΎ ΠΌΠ°ΡΡΡΡΡΠ½ΡΠΌ ΡΠ²ΡΠ·ΡΠΌ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡΡΡ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΏΡΠΎΠ΅ΠΊΡΠ° ΠΠ 05133699 Β«ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΠΎΠ½Π½ΠΎ-ΡΠ΅Π»Π΅ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΊΠΈΠ±Π΅ΡΡΠ΅Ρ
Π½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ΅Π΄ΡΡΠ² Π΄Π»Ρ ΠΈΠ½ΡΠ΅Π»Π»Π΅ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π³ΠΎΡΠΎΠ΄Π°Β». The article discusses the concept of constructing a repository of data on travel routes for the intellectual transport system of the city. The mathematical apparatus of a formalized description of a transport system based on a hypernet, whose arcs are paths of movement, is given. A recursive algorithm for obtaining data on paths of movement, as well as a mechanism for using adjacency matrices for route connections, is considered. Research is carried out as part of the project AR05133699 βResearch and development of innovative telecommunication technologies using modern cyber-technical means for the intellectual transport system of the cityβ
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS At baseline, the mean (Β±SD) age of the patients was 45.1Β±12.0 years, the mean weight was 106.2Β±21.4 kg, and the mean BMI was 38.3Β±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4Β±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8Β±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONS In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.)
Vliyanie polimorfizma gena angiotenzin-I-prevrashchayushchego fermenta (APF) na antiproteinuricheskiy effekt ingibitorov APF u molodykh bol'nykh insulinzavisimym sakharnym diabetom
ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΡΠΈΡΠΎΠΊΠΎ ΠΎΠ±ΡΡΠΆΠ΄Π°Π΅ΡΡΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π΄ΠΈΠ°Π±Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠΈ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° Π°Π½Π³ΠΈΠΎΡΠ΅Π½Π·ΠΈΠ½-1-ΠΏΡΠ΅Π²ΡΠ°ΡΠ°ΡΡΠ΅Π³ΠΎ ΡΠ΅ΡΠΌΠ΅Π½ΡΠ° (ΠΠ‘Π). ΠΡΡ
ΠΎΠ΄Ρ ΠΈΠ· Π²Π΅Π΄ΡΡΠ΅ΠΉ ΡΠΎΠ»ΠΈ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΠ, ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΡΠΎΠ³ΠΎ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ Π°Π½Π³ΠΈΠΎΡΠ΅Π½Π·ΠΈΠ½-1-ΠΏΡΠ΅Π²ΡΠ°ΡΠ°ΡΡΠ΅Π³ΠΎ ΡΠ΅ΡΠΌΠ΅Π½ΡΠ° (ΠΠΠ€). ΠΠ΄Π½Π°ΠΊΠΎ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΌ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΡΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΌΠ°Π»ΠΎ ΠΈΠ·ΡΡΠ΅Π½Π°. ΠΠΎΠΏΡΠΎΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ, Π΄ΠΎΠ· ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΈ ΡΡΠ΅Π±ΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΡΡΠΎΡΠ½Π΅Π½ΠΈΡ. Π¦Π΅Π»Ρ. Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΠΠ€ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΠ Ρ Π΄Π΅ΡΠ΅ΠΉ, ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² ΠΈ ΠΌΠΎΠ»ΠΎΠ΄ΡΡ
Π»ΡΠ΄Π΅ΠΉ Ρ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠΌ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ, Π·Π°Π±ΠΎΠ»Π΅Π²ΡΠΈΡ
ΠΠΠ‘Π Π² Π΄Π΅ΡΡΡΠ²Π΅, Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π²ΠΈΠ΄Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, Π΄ΠΎΠ·Ρ, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π³Π΅Π½Π° ΠΠ‘Π. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ 73 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΠ (Π½Π° ΡΡΠ°Π΄ΠΈΠΈ ΠΠΠ£ ΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΠΈ) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 12 Π»Π΅Ρ Π΄ΠΎ 21 Π³ΠΎΠ΄Π° Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΎΡ 2 Π΄ΠΎ 18 Π»Π΅Ρ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ Π² ΠΈΠ½ΡΠ΅Π½ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅. ΠΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ Π³Π»ΠΈΠΊΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π³Π΅ΠΌΠΎΠ³Π»ΠΎΠ±ΠΈΠ½ (HbA1Π‘) ΠΈ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΡ (ΠΠΠ£) Π΄Π²Π°ΠΆΠ΄Ρ Π² Π½ΠΎΡΠ½ΠΎΠΉ ΠΏΠΎΡΡΠΈΠΈ ΠΌΠΎΡΠΈ ΠΏΠΎ ΠΏΠΎΠ»ΠΎΡΠΊΠ°ΠΌ "ΠΠΈΠΊΡΠ°Π»Ρ-ΡΠ΅ΡΡ Π" ΠΈ ΠΎΠ΄Π½ΠΎΠΊΡΠ°ΡΠ½ΠΎ Π² ΡΡΡΠΎΡΠ½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΌΠΎΡΠΈ ΡΡΡΠ±ΠΎΠ΄ΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π° Π°Π²ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΎΡΠΎΠΌΠ΅ΡΡΠ΅ "Spectrum Abbott laboratory". ΠΠ»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΠ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π³Π΅Π½Π°, ΠΊΠΎΡΠΎΡΡΠΉ ΠΊΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ Π½Π° 17-ΠΉ Ρ
ΡΠΎΠΌΠΎΡΠΎΠΌΠ΅ ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ Π² Π²ΠΈΠ΄Π΅ 2 Π°Π»Π»Π΅Π»Π΅ΠΉ I ΠΈ D ΠΏΠΎ ΡΠΈΠΏΡ Π²ΡΡΠ°Π²ΠΊΠΈ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΡ Π²ΡΡΠ°Π²ΠΊΠΈ. ΠΠ·ΡΡΠ΅Π½Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π΄Π²ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈΠ· Π³ΡΡΠΏΠΏΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΠΠ€ - ΡΠ½Π°Π»Π°ΠΏΡΠΈΠ»Π° Π² Π΄ΠΎΠ·Π΅ ΠΈ ΡΠ°ΠΌΠΈΠΏΡΠΈΠ»Π°. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 12 Π½Π΅Π΄ 46 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (38 Ρ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠ΅ΠΉ ΠΈ 8 Ρ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΠ΅ΠΉ) ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΠ΅Π½ΠΈΡΠ΅ΠΊ Π² Π΄ΠΎΠ·Π΅ 5 ΠΌΠ³ Π² ΡΡΡΠΊΠΈ, 28 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (24 Ρ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠ΅ΠΉ ΠΈ 4 Ρ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΠ΅ΠΉ) ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΡΠΈΡΠ°ΡΠ΅ Π² Π΄ΠΎΠ·Π΅ 2,5 ΠΌΠ³ Π² ΡΡΡΠΊΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠ΅ΠΉ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° DD. ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π±Π΅Π· Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠΈ - Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ², ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
Π°Π»Π»Π΅Π»Ρ I. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΡ Ρ Π΄Π°Π½Π½ΡΠΌΠΈ Π΄ΡΡΠ³ΠΈΡ
Π°Π²ΡΠΎΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΌΠΈ Π½Π° Π²Π·ΡΠΎΡΠ»ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ‘Π ΠΈΠ· ΠΌΠΎΡΠΊΠΎΠ²ΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ, Π³Π΄Π΅ Π±ΡΠ»Π° ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ I / D ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠΌ Π³Π΅Π½Π° ΠΠ‘Π ΠΈ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠΈ. ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ Π°Π½ΡΠΈΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠ° ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΠΠ€ ΠΎΡ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ ΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΠΠ£ ΠΌΠ΅Π½Π΅Π΅ 100 ΠΌΠ³/ΡΡΡ ΡΠ°ΡΡΠΎΡΠ° Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 80.9% ΠΈ Π±ΡΠ»Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ 100-300 ΠΌΠ³/ΡΡΡ, Π³Π΄Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ½ΠΈΠ·ΠΈΠ»Π°ΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π² 2 ΡΠ°Π·Π°. Π Π³ΡΡΠΏΠΏΠ΅ Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΠΠ£ Π±ΠΎΠ»Π΅Π΅ 300 ΠΌΠ³/ΡΡ Ρ ΡΠ»ΡΡΠ°ΠΈ Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡ Π° Π±ΡΠ»ΠΈ ΡΠ΅Π΄ΠΊΠΈΠΌΠΈ (37%) ΠΈ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΡΠΎΠ»ΡΠΊΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ£ (ΡΠΊΡΠΊΡΠ΅ΡΠΈΡ Π°Π»ΡΠ±ΡΠΌΠΈΠ½Π° Ρ ΠΌΠΎΡΠΎΠΉ 300 - 500 ΠΌΠ³/ΡΡΡ). ΠΡΠ²ΠΎΠ΄Ρ. Π£ Π½ΠΎΡΠΌΠΎΡΠ΅Π½Π·ΠΈΠ²Π½ΡΡ
ΠΌΠΎΠ»ΠΎΠ΄ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ‘Π Π½Π° ΡΡΠ°Π΄ΠΈΠΈ Π½Π°ΡΠΈΠ½Π°ΡΡΠ΅ΠΉΡΡ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠΈ, Π² Π³Π΅Π½ΠΎΡΠΈΠΏΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΡΠΎΠ΄Π΅ΡΠΆΠ°Π»ΡΡ Π΄Π°ΠΆΠ΅ ΠΎΠ΄ΠΈΠ½ Π°Π»Π»Π΅Π»Ρ I (II ΠΈ ID), ΠΎΡΠΌΠ΅ΡΠ΅Π½ Π²ΡΡΠΎΠΊΠΈΠΉ Π°Π½ΡΠΈΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΡΠ΅Π½ΠΈΡΠ΅ΠΊΠ° ΠΈ ΡΡΠΈΡΠ°ΡΠ΅ Π² ΡΡΠ±ΠΏΡΠ΅ΡΡΠΎΡΠ½ΡΡ
Π΄ΠΎΠ·Π°Ρ
. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ DD ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΡΠ»Π° Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅. ΠΡΡΠ²Π»Π΅Π½Π½Π°Ρ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ID ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠΌ Π³Π΅Π½Π° ΠΠ‘Π ΠΈ Π°Π½ΡΠΈΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΠΠ€ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π΄ΠΈΠ°Π±Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΠ΅ΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π² Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
BACKGROUND: Obesity is a chronic disease with serious health consequences, but
weight loss is difficult to maintain through lifestyle intervention alone.
Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential
benefit for weight management at a once-daily dose of 3.0 mg, injected
subcutaneously.
METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who
did not have type 2 diabetes and who had a body-mass index (BMI; the weight in
kilograms divided by the square of the height in meters) of at least 30 or a BMI
of at least 27 if they had treated or untreated dyslipidemia or hypertension. We
randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous
injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244
patients); both groups received counseling on lifestyle modification. The
coprimary end points were the change in body weight and the proportions of
patients losing at least 5% and more than 10% of their initial body weight.
RESULTS: At baseline, the mean (Β±SD) age of the patients was 45.1Β±12.0 years, the
mean weight was 106.2Β±21.4 kg, and the mean BMI was 38.3Β±6.4; a total of 78.5% of
the patients were women and 61.2% had prediabetes. At week 56, patients in the
liraglutide group had lost a mean of 8.4Β±7.3 kg of body weight, and those in the
placebo group had lost a mean of 2.8Β±6.5 kg (a difference of -5.6 kg; 95%
confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward
imputation). A total of 63.2% of the patients in the liraglutide group as
compared with 27.1% in the placebo group lost at least 5% of their body weight
(P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body
weight (P<0.001). The most frequently reported adverse events with liraglutide
were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the
patients in the liraglutide group and in 5.0% of the patients in the placebo
group.
CONCLUSIONS: In this study, 3.0 mg of liraglutide, as an adjunct to diet and
exercise, was associated with reduced body weight and improved metabolic control.
(Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839
ClinicalTrials.gov number, NCT01272219.)